Search results
Pfizer agrees to settle over 10K lawsuits linking Zantac to cancer
New York Post· 11 hours agoBy 1988, it was the world’s best selling drug as patients reported benefits for conditions such as...
Teva, Medincell's schizophrenia drug succeeds in late-stage study
Reuters via Yahoo News· 16 hours agoU.S.-listed shares of Teva were up 3.3% at $14.41 in premarket trading. The companies hope that the ...
Pfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reports
Reuters via Yahoo News· 13 hours agoThe agreements cover cases in U.S. state courts but don't completely resolve the company's exposure...
The FTC is challenging 'junk' drug patents. Here's what they are and why they matter
Quartz· 6 hours agoThe FTC argues that improper or inaccurate listings delay more affordable generic and biosimilar...
AstraZeneca withdraws Covid vaccine worldwide after admitting it can cause rare blood clots
The Independent via Yahoo News· 14 hours agoThe admission came after the company was slapped with a class action lawsuit in the UK, which...
Merck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.
Quartz· 18 hours agoEvery pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar ...
McKesson misses quarterly estimates as US pharmaceuticals segment weighs
Reuters· 1 day ago, opens new tab reported weaker-than-expected quarterly revenue and profit on Tuesday due to slump in demand for the company's branded and specialty drugs that dragged sales ...
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Zacks via Yahoo Finance· 3 days agoThe earnings season for the drug/biotech sector is now in its final lap, with two S&P 500 companies,...
How sham patents are hurting the pharma industry
Pharmaceutical Technology via Yahoo Finance· 2 days ago“[The Orange Book] is a very unusual system that has greatly encouraged generic companies to challenge patents,” Singla continues. Singla specialises in...
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Digital Journal· 7 hours agoReports Net Revenues of $171.8 Million for the Three Months Ended March 31, 2024 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 8, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" ...